Tuesday, September 8, 2026 at 12:00 PM–1:00 PM EDT                        Pricing: Free for Members and $99 for Non-Members

Program Description

Federal drug pricing policy is moving rapidly from the Medicare Drug Price Negotiation Program (MFP) toward renewed interest in most-favored-nation (MFN)–style approaches, with ripple effects far beyond their stated intent. As price controls intersect with rebates, Medicaid best price, 340B, and growing price transparency, traditional pricing and formulary strategies are being tested in real time. Drawing on perspectives from policy, economics, Medicaid, employers, and formulary leaders, this session unpacks how these policies transmit through markets—and where theory breaks down in practice. Attendees will explore unintended consequences, including launch delays, benefit disruptions, rebate erosion, and shifting stakeholder trust. The discussion emphasizes practical implications for payers navigating affordability pressures, political uncertainty, and evolving pricing architectures.